Navigation Links
Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Date:10/15/2007

ng statements relating to Lexicon's clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
3. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and NEW YORK ... As the leading distributor of market intelligence, ... new research report by IQ4I Research and Consultancy focusing ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast to ...
(Date:11/26/2014)... 25, 2014  At the American Dental Association,s Annual ... October, KaVo Kerr Group was honored to be part ... the opportunity to see and test the Best of ... deliver lectures on the latest developments in dental technology. ... new DEXIS CariVu Caries Detection Device and Kerr Demi ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 25, 2014 ... Royal Philips (NYSE: PHG ... Food and Drug Administration (FDA) for its IQon ... spectral imaging. This first-of-its kind technology adds a new ... and offering the ability to characterize structures based on ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
(Date:11/27/2014)... In addition to a new dessert recipe ... this holiday season and become educated about the warning ... over the holidays may raise questions about the physical ... in cognitive ability can occur with age, serious memory ... the difference between normal aging and more serious problems ...
(Date:11/26/2014)... Angeles, CA (PRWEB) November 26, 2014 ... to treat themselves this holiday season! With Parsa Mohebi ... incredible 10% off of their next FUE procedure, making ... transplant. , FUE—which stands for “Follicular Unit Extraction”—is an ... advantages over traditional “strip” Follicular Unit Transplantation (FUT). FUE, ...
(Date:11/26/2014)... 2014 Boxing Day is traditionally the ... receive gifts, known as a "Christmas box", from their ... With the coming of Boxing Day, some people may ... before every business opportunity, and it has recently announced ... site-wide promotion for its global customers. Then people can ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... surgeon and Distinguished Teaching Professor in the ... Center, recently discussed facial fat compartments, fat grafting, ... Surgery, The Meeting," an annual conference held by ... importance and intricacies of this underlying facial structure ...
(Date:11/26/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... understand what they,re saying, a new study suggests they are ... way. Past research has shown that dogs respond to ... and the emotional tone, said study author Victoria Ratcliffe. ... canine brain, according to Ratcliffe, a Ph.D. candidate at the ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 2Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 3Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 5Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:Tbdress.com: Best Boxing Day Sales For Ladies Worldwide 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3
... of patients who contracted Hepatitis C in the 1980s had ... condition.// This is same as delayed is denied. ... McGuire, after studying documents obtained through the Freedom of Information ... and advise patients and that some had infected their partners. ...
... England is at its lowest ever with 8.5 deaths per 100,000 ... also noted that for the first time in 25 years there ... committing suicide. ,The British government had pledged to cut ... in 2002. The current report was jointly issued by the Department ...
... inflammation. According to a German clinical trail conducted by ... found that high doses of Vitamin D supplements inhibit ... function. The results of the study were published in ... researchers studied the effect of a high-dose vitamin D3 ...
... experts about the hearing loss caused by the MP3 ... without paying// any heed to those warnings. But sensing ... started limiting the volume on the devices. ,The ... damage to the ears associated with MP3 players. The ...
... to avoid controversial breast enlargement gel injections after six ... ,Fifty-three women from Hong Kong have complained of ... gel injected into their breasts. ,Six women ... after suffering severe complications from the operation, a spokesman ...
... an outbreak of malaria that claimed 35 lives and affected ... across Assam and medical teams are working on a war ... Bhumidhar Barman told IANS. ,Most of the casualties ... Lakhimpur, besides from areas bordering Bhutan. ,"Some 35 ...
Cached Medicine News:Health News:High Dose Of Vitamin D3 A Boon for Patients Suffering From Heart Failure 2Health News:Sensing The Health Hazard MP3 Makers Tone Down The Volume 2Health News:Malaria Claims 35 Lives In Assam 2
Jaffe tying forceps is very delicate with smooth jaws, straight, 6 mm long platform. For 8-0 to 11-0 sutures....
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Medicine Products: